摘要
目的 观察清金化痰汤联合头孢哌酮钠舒巴坦钠治疗非小细胞肺癌(Non-small-cell lung cancer,NSCLC)患者放化疗后下呼吸道感染的临床疗效。方法 选取2019年6月—2024年6月南通市肿瘤医院收治的100例NSCLC患者,按随机数字表法分为对照组和观察组,每组各50例。对照组给予头孢哌酮钠舒巴坦钠治疗,观察组给予头孢哌酮钠舒巴坦钠联合清金化痰汤治疗。治疗10 d后,观察比较两组患者临床疗效、不良反应情况、治疗前后临床症状积分变化、肿瘤标志物[癌抗原125(Carbohydrate antigen 125,CA125)、癌胚抗原(Carcinoembryonic antigen,CEA)、神经元特异烯醇化酶(Neuron-specific enolase,NSE)]、炎症因子[降钙素原(Procalcitonin,PCT)、C反应蛋白(C-reactive protein,CRP)、肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)]。结果 治疗后观察组临床总有效率94.00%(47/50)明显高于对照组80.00%(40/50),差异有统计学意义(P<0.05)。治疗后两组患者临床症状积分均较治疗前降低,差异有统计学意义(P<0.05);且观察组临床症状积分明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者CA125、CEA、NSE水平均较治疗前降低,差异有统计学意义(P<0.05);且观察组CA125、CEA、NSE水平明显低于对照组,差异有统计学意义(P<0.05)。治疗后两组患者PCT、CRP、TNF-α水平均较治疗前降低,差异有统计学意义(P<0.05);且观察组PCT、CRP、TNF-α水平明显低于对照组,差异有统计学意义(P<0.05)。治疗期间,观察组不良反应发生率26.00%(13/50)明显低于对照组48.00%(24/50),差异有统计学意义(P<0.05)。结论 清金化痰汤联合头孢哌酮钠舒巴坦钠可有效治疗NSCLC患者放化疗后下呼吸道感染,疗效确切,还能改善患者临床症状、调节肿瘤标志物及炎症因子水平,且可进一步减轻治疗不良反应。
Objective To observe the clinical efficacy of Qingjin Huatan Decoction combined with cefoperazone sodium on lower respiratory infection in patients with non-small-cell lung cancer(NSCLC)after chemoradiotherapy.Methods One hundred NSCLC patients treated at Nantong Tumor Hospital from June 2019 to June 2024 were selected and divided into a control group and an observation group by the random number table method,with 50 patients in each group.Both groups received cefoperazone sodium and sulbactam sodium,while the observation group additionally received Qingjin Huatan Decoction.After 10 days of treatment,clinical efficacy and adverse reactions were compared between the two groups,as well as aspects below before and after treatment:clinical symptom score changes,tumor markers[carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),and neuron-specific enolase(NSE)],and inflammatory factors[procalcitonin(PCT),C-reactive protein(CRP),and tumor necrosis factor-α(TNF-α)].Results After treatment,the total clinical effective rate of the observation group was 94.00%(47/50),which was significantly higher than that of the control group at 80.00%(40/50)(P<0.05).The clinical symptom scores were decreased in both groups(P<0.05),with the scores being significantly lower in the observation group(P<0.05).The CA125,CEA,and NSE levels were decreased in both groups(P<0.05),with the levels being significantly lower in the observation group(P<0.05).Similarly,the PCT,CRP,and TNF-αlevels were decreased in both groups(P<0.05),with the levels being significantly lower in the observation group(P<0.05).During the treatment period,the incidence of adverse reactions in the observation group was 26.00%(13/50),significantly lower than that in the control group at 48.00%(24/50)(P<0.05).Conclusion Qingjin Huatan Decoction combined with cefoperazone sodium can effectively treat lower respiratory infection in NSCLC patients after chemoradiotherapy,with significant therapeutic effects.Additionally,the Decoction can improve clinical symptoms,regulate the tumor marker and inflammatory factor levels,and further reduce adverse reactions to the treatment.
作者
解金凤
羌曹霞
朱雪娟
金小洁
XIE Jin-feng;QIANG Cao-xia;ZHU Xue-juan;JIN Xiao-jie(Nantong Tumor Hospital&Affiliated Tumor Hospital of Nantong University,Nantong Jiangsu 226361;Affiliated Hospital of Nantong University,Nantong Jiangsu 226006)
出处
《世界中西医结合杂志》
2025年第11期2211-2215,共5页
World Journal of Integrated Traditional and Western Medicine
基金
南通市卫生健康委科研课题(指令性)立项课题(MS2022049)。
关键词
清金化痰汤
非小细胞肺癌
放化疗
下呼吸道感染
Qingjin Huatan Decoction
Non-small Cell Lung Cancer
Chemoradiotherapy
Lower Respiratory Infection
